Could Medicure Inc Change Direction After Reaching 52-Week High?

 Could Medicure Inc Change Direction After Reaching 52 Week High?

The stock of Medicure Inc (CVE:MPH) hit a new 52-week high and has $8.62 target or 4.00% above today’s $8.29 share price. The 7 months bullish chart indicates low risk for the $132.07 million company. The 1-year high was reported on Nov, 29 by Barchart.com. If the $8.62 price target is reached, the company will be worth $5.28 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 5,313 shares traded hands. Medicure Inc (CVE:MPH) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.

More recent Medicure Inc (CVE:MPH) news were published by: Midasletter.com which released: “S&P/TSX Venture Composite Index Movers: GoldMoney Inc., Medicure Inc …” on February 02, 2016. Also Seekingalpha.com published the news titled: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” on February 17, 2016. Marketwired.com‘s news article titled: “Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore” with publication date: July 03, 2014 was also an interesting one.

Medicure Inc. is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The company has a market cap of $132.07 million. The Firm operates in the biopharmaceutical industry segment. It has a 29.22 P/E ratio. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc.

MPH.V Company Profile

Medicure Inc. (Medicure), incorporated on February 23, 2000, is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The Firm operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. The Firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment